Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies

The discovery of naturally occurring heavy chain only antibodies and their further development into small recombinant ‘nanobodies’ offers attractive applications in drug targeting. Here, we describe the properties of nanobodies that have been developed to target the epidermal growth factor receptor...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutical sciences 2012-03, Vol.45 (4), p.399-407
Main Authors: Altintas, Isil, Kok, Robbert Jan, Schiffelers, Raymond M.
Format: Article
Language:English
Subjects:
Animals
Antibodies - pharmacology
Antibodies - therapeutic use
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibody
Biological and medical sciences
Drug delivery systems
Epidermal growth factor receptor
General pharmacology
Humans
Immunoglobulin Heavy Chains - pharmacology
Immunoglobulin Heavy Chains - therapeutic use
Medical sciences
Nanobody
Nanoparticles - therapeutic use
Neoplasms - drug therapy
Neoplasms - metabolism
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Receptor, Epidermal Growth Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery of naturally occurring heavy chain only antibodies and their further development into small recombinant ‘nanobodies’ offers attractive applications in drug targeting. Here, we describe the properties of nanobodies that have been developed to target the epidermal growth factor receptor (EGFR) and contrast these to the characteristics of heavy chain only antibodies and conventional antibodies. EGFR is overexpressed in many tumors and is an attractive target for tumor-directed drug targeting.
ISSN:0928-0987
1879-0720
DOI:10.1016/j.ejps.2011.10.015